Skip to content
DataLookout
Menu

NCT07015697

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Final enrollment: 17 participants (planned 76)
  2. Notable Eligibility criteria shortened, about 469 words
    • Trial sites expanded: 26 → 31 locations
    v9
  3. Minor Study sites: 23 to 26v8
  4. Notable Eligibility criteria shortened, about 22 wordsv7
  5. Minor Study sites: 13 to 23v6
Show 4 earlier versionsHide 4 earlier versions
  1. Minor Study sites: 5 to 13v5
  2. Minor Study sites: 2 to 5
    • Start date changed from estimate of Aug 29, 2025 to Jul 17, 2025
    v4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    v3
  4. Notable Start date: Jun 30, 2025 to Aug 29, 2025
    • Eligibility criteria expanded, about 45 words
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants Experiencing a Treatment Emergent Adverse Event (TEAE)
Timeframe: From the start of trial intervention to 21 days after the last dose, up to approximately 9 months
Area Under Curve (AUC)
Timeframe: From the start of trial intervention to last dose, up to approximately 9 months
Number of Participants with Dose limiting toxicities (DLT) During the Dose-Escalation Phase
Timeframe: From the start of trial intervention to 21 days after the last dose, up to approximately 9 months

Secondary (3)

Percentage of Participants with Anti-Drug Antibody (ADAs)
Overall Response Rate (ORR)
Disease Control Rate (DCR)

Arms and interventions

Part 1 (Dose Escalation)Experimental

Participants will receive Trastuzumab Deruxtecan subcutaneously at escalating doses. The recommended dose for expansion (RDE) will be calculated using data collected from this population.

Part 2 (Dose Expansion)Experimental

Participants will receive Trastuzumab Deruxtecan subcutaneously at the recommended dose for expansion (RDE)

Drugs: Trastuzumab Deruxtecan

Sites

31 sites in 7 countries

United States 6, Brazil 5, Japan 5, South Korea 5, Taiwan 5, Spain 3, France 2